BMS-813160 is under clinical development by Bristol-Myers Squibb and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BMS-813160’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BMS-813160 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BMS-813160 overview

BMS-813160 is under development for solid tumor, metastatic colorectal cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, renal cell carcinoma and hepatocellular carcinoma. It is administered orally as a capsule. The drug candidate is a dual CCR2/CCR5 antagonist. BMS-813160 was also under development for the treatment of nephropathy involving residual macroalbuminuria in type 2 diabetes, diabetic kidney disease patients and accelerated intimal hyperplasia, non-small cell lung cancer.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View BMS-813160 LOA Data

Report Segments
  • Innovator
Drug Name
  • BMS-813160
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.